We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC
BCLI

Delisted

BCLI was delisted on the 17th of July, 2025.

Back to rankings

39 hedge funds and large institutions have $9.38M invested in BRAINSTORM CELL THERAPUTC in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 2

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

77% more capital invested

Capital invested by funds: $5.29M → $9.38M (+$4.1M)

15% more funds holding

Funds holding: 34 → 39 (+5)

0.21% more ownership

Funds ownership: 0.59% → 0.8% (+0.21%)

Holders
39
Holders Change
+5
Holders Change %
+14.71%
% of All Funds
0.89%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
14
Reduced
2
Closed
4
Calls
$212K
Puts
–
Net Calls
+$212K
Net Calls Change
+$198K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$3.56M
2
JP Morgan Chase
JP Morgan Chase
New York
+$510K
3
Renaissance Technologies
Renaissance Technologies
New York
+$103K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$76.7K
5
CPP
Crow Point Partners
Massachusetts
+$71.9K

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$1.26M
2
Deutsche Bank
Deutsche Bank
Germany
-$94K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$15.1K
4
SPIA
Steward Partners Investment Advisory
New York
-$9K
5
UBS Group
UBS Group
Switzerland
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
WT
26
Washington Trust
Rhode Island
$10K +$9.82K +167 New
Bank of Montreal
27
Bank of Montreal
Ontario, Canada
$8K – – –
IFAM
28
Institutional & Family Asset Management
Colorado
$8K – – –
TRCT
29
Tower Research Capital (TRC)
New York
$5K +$647 +11 +14%
ASN
30
Advisory Services Network
Georgia
$2K – – –
CF
31
Centaurus Financial
California
$2K +$1.59K +27 New
Citigroup
32
Citigroup
New York
$1K – – –
MCM
33
Monument Capital Management
Virginia
$1K – – –
US Bancorp
34
US Bancorp
Minnesota
$1K – – –
BCA
35
Bay Colony Advisors
Massachusetts
$1K +$765 +13 New
FLI
36
Family Legacy Inc
South Carolina
$1K +$765 +13 New
TDC
37
Thompson Davis & Co
Virginia
$1K +$765 +13 New
WOC
38
West Oak Capital
California
$585 – – –
EMG
39
ETF Managers Group
New Jersey
$102 -$3.94K -67 -3%
PA
40
Perceptive Advisors
New York
– -$1.26M -26,667 Closed
Deutsche Bank
41
Deutsche Bank
Germany
– -$94K -1,994 Closed
SPIA
42
Steward Partners Investment Advisory
New York
– -$9K -200 Closed
UBS Group
43
UBS Group
Switzerland
– -$5K -103 Closed
1
2

BCLI Hedge Fund Activity: Q2 2018 in Review

39 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2018, worth a combined $9.38M — up 77% from $5.29M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new BCLI positions and 4 closed out — a net gain of 5 holders — while 14 added to existing stakes and 2 trimmed.

The largest buyer was Sabby Management, adding an estimated $3.56M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $1.26M sold.

  • 39 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2018, up from 34 in Q1 2018.
  • Funds reported $9.38M of BRAINSTORM CELL THERAPUTC stock for Q2 2018, up 77% quarter-over-quarter.
  • 9 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2018 and 4 closed out, a net change of +5 holders.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2018 was Sabby Management, an estimated $3.56M added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q2 2018 was Perceptive Advisors, an estimated $1.26M sold.

Based on aggregated 13F filings for Q2 2018.